JP Morgan Chase’s Akoya BioSciences AKYA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-139,973
| Closed | -$182K | – | 7366 |
|
|
2025
Q2 | $182K | Sell |
139,973
-271,638
| -66% | -$327K | ﹤0.01% | 5285 |
|
|
2025
Q1 | $572K | Buy |
411,611
+363,298
| +752% | +$795K | ﹤0.01% | 4682 |
|
|
2024
Q4 | $111K | Buy |
48,313
+36,093
| +295% | +$95.6K | ﹤0.01% | 5717 |
|
|
2024
Q3 | $33.2K | Buy |
12,220
+350
| +3% | +$855 | ﹤0.01% | 6117 |
|
|
2024
Q2 | $27.8K | Sell |
11,870
-2,827
| -19% | -$9.02K | ﹤0.01% | 6054 |
|
|
2024
Q1 | $68.9K | Sell |
14,697
-12
| -0.1% | -$62 | ﹤0.01% | 5816 |
|
|
2023
Q4 | $71.8K | Hold |
14,709
| – | – | ﹤0.01% | 5879 |
|
|
2023
Q3 | $68.4K | Buy |
14,709
+200
| +1% | +$1.15K | ﹤0.01% | 5688 |
|
|
2023
Q2 | $107K | Buy |
14,509
+2,415
| +20% | +$16.1K | ﹤0.01% | 5429 |
|
|
2023
Q1 | $99K | Buy |
12,094
+3,154
| +35% | +$33K | ﹤0.01% | 5434 |
|
|
2022
Q4 | $85K | Buy |
8,940
+323
| +4% | +$3.97K | ﹤0.01% | 5418 |
|
|
2022
Q3 | $101K | Buy |
8,617
+186
| +2% | +$2.45K | ﹤0.01% | 5281 |
|
|
2022
Q2 | $108K | Buy |
8,431
+2,138
| +34% | +$22.2K | ﹤0.01% | 5368 |
|
|
2022
Q1 | $69K | Buy |
6,293
+408
| +7% | +$4.73K | ﹤0.01% | 5659 |
|
|
2021
Q4 | $90K | Buy |
5,885
+2,953
| +101% | +$38.6K | ﹤0.01% | 5729 |
|
|
2021
Q3 | $41K | Sell |
2,932
-7,009
| -71% | -$117K | ﹤0.01% | 5890 |
|
|
2021
Q2 | $193K | Buy |
+9,941
| New | +$205K | ﹤0.01% | 5264 |
|
JP Morgan Chase's AKYA Position: Q3 2025 in Review
JP Morgan Chase sold out of Akoya BioSciences (AKYA) in Q3 2025, closing a stake of 139,973 shares — an estimated $182K sold.
JP Morgan Chase first reported a position in AKYA in Q2 2021 and held it in 17 quarters. The position peaked at $572K in Q1 2025. 0 funds tracked by Wall St. Rank hold AKYA as of Q3 2025.
- JP Morgan Chase reported no remaining Akoya BioSciences position as of Q3 2025 after selling out during the quarter.
- JP Morgan Chase sold 139,973 Akoya BioSciences shares in Q3 2025, an estimated $182K.
- JP Morgan Chase first reported a position in Akoya BioSciences in Q2 2021 and held it in 17 quarters.
- JP Morgan Chase's Akoya BioSciences position peaked at $572K in Q1 2025.
- 0 funds tracked by Wall St. Rank held Akoya BioSciences as of Q3 2025.
Based on JP Morgan Chase's 13F filing for Q3 2025, filed 7 Nov 2025.